Table I.

Characteristics of the 511 patients registered on study.

	Total		Randomized		Not randomized
Characteristic	n	%	n	%	n	%
Male	286	56.0%	78	49.7%	208	58.8%
Female	225	44.0%	79	50.3%	146	41.2%
B symptoms	42	8.4%	12	7.7%	30	8.7%
Stage
I	54	11.3%	21	14.1%	33	10.1%
II	76	16.0%	20	13.4%	56	17.1%
III	88	18.5%	31	20.8%	57	17.4%
V	258	54.2%	77	51.7%	181	55.4%
Extranodal sites
0	409	81.8%	130	83.3%	279	81.1%
1	57	11.4%	20	12.8%	37	10.8%
2	18	3.6%	4	2.6%	14	4.1%
3+	16	3.2%	2	1.3%	14	4.1%
Performance status
0	371	74.5%	125	80.1%	246	71.9%
1	116	23.3%	28	18.0%	88	25.7%
2	11	2.2%	3	1.9%	8	2.3%
IWF grade
Low	191	38.8%	73	47.4%	118	34.9%
Intermediate	239	48.6%	68	44.2%	171	50.6%
High	37	7.5%	6	3.9%	31	9.2%
Miscellaneous	25	5.1%	7	4.6%	18	5.3%
Disease status
Sensitive	451	91.7%	145	95.4%	306	90.0%
Resistant	41	8.3%	7	4.6%	34	10.0%
Age (years)
20–29	20	3.9%	3	1.9%	17	4.8%
30–39	83	16.2%	30	10.1%	53	15.0%
40–49	159	31.1%	50	31.9%	109	30.8%
50–59	175	34.2%	57	36.3%	118	33.3%
60–69	73	14.3%	17	10.8%	56	15.8%
70 +	1	0.2%	0	0%	1	0.3%
Median/range	49	20–70	48	26–69	49	20–70
LDH, median/range	252	65–9828	215	74–1267	278	65–9828

IWF, International Working Formulation; LDH, lactate dehydrogenase.